VSTM earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E -2.36. Updated 2026-07-23.
Verastem (VSTM) Research Hub
Verastem (VSTM) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 7.32 USD (-7.81%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -2.36, market cap 0.41B. This hub links to the full technical, earnings and options research available for VSTM.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 7.32 USD (-7.81%) |
| 52-week range | 3.44 USD – 8.54 USD |
| Trend regime | Range |
| 14-day RSI | 56.8 (Bullish) |
| Trailing P/E | -2.36 |
| Market cap | 0.41B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for VSTM
Covered Call on VSTM: how it works, illustrative setup around the real 7.32 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on VSTM: how it works, illustrative setup around the real 7.32 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on VSTM: how it works, illustrative setup around the real 7.32 USD price, max profit/loss, breakeven and when to use it. Educational.
VSTM technical analysis: range, last 7.32 USD, RSI 56.8, 52w range 3.44 USD–8.54 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is VSTM in?
Verastem (VSTM) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is VSTM in an uptrend or downtrend?
As of 2026-09-11, VSTM is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is VSTM's trailing P/E ratio?
VSTM's trailing P/E is -2.36, with a market cap of 0.41B. See the earnings research page for full valuation detail.
When does VSTM next report earnings?
VSTM is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -0.46 USD.